Subscribe to RSS
DOI: 10.1055/s-2005-836649
© Georg Thieme Verlag Stuttgart · New York
Wertigkeit der Positronenemissionstomographie für das Staging beim Ösophaguskarzinom
The Value of Positron Emission Tomography for Staging of Esophageal CancerPublication History
Publication Date:
13 September 2005 (online)
Zusammenfassung
Der Wert der Positronenemissionstomographie mit 18F-18-Fluorodesoxyglukose (FDG-PET) für das primäre Staging und das posttherapeutische Restaging beim Ösophaguskarzinom wurde in verschiedenen aktuellen Studien untersucht. Die meisten Studien vergleichen die Ergebnisse der FDG-PET mit denen der Computertomographie und/oder der endoskopischen Ultraschalluntersuchung. Die verschiedenen Autoren stimmen darin überein, dass der klinische Einsatz der FDG-PET sowohl die Identifikation von Lymphknotenmetastasen als auch die von Metastasen in anderen Organen verbessert. Eine zunehmende Zahl von Untersuchern zeigte darüber hinaus die Aussagekraft der FDG-PET für die Analyse des Ansprechens des Ösophaguskarzinoms bei neoadjuvanter Radiochemotherapie sowie für die Vorhersage des Langzeitüberlebens.
Abstract
Positron emission tomography with 18F-Florodesoxyglucose (FDG-PET) was recently evaluated by several studies for staging and posttherapeutical re-staging of esophageal cancer. Most studies compared the FDG-PET results to CT and/or endoscopic ultrasonography. The different authors agreed that the use of FDG-PET improves the identification of lymph node metastases as well as of metastases in other organs. A growing number of investigators also showed the value of FDG-PET for the response analysis after neoadjuvant or concurrent radiochemotherapy resp. the prediction of the long-term survival.
Schlüsselwörter
Positronenemissionstomographie - PET - Ösophaguskarzinom - Staging
Key words
positron emission tomography - PET - esophageal cancer - staging
Literatur
- 1 Dietlein M, Weber W, Schwaiger M, Schicha H. [18F-Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer]. Nuklearmedizin. 2003; 42 145-156
- 2 Dehdashti F, Siegel B A. Neoplasms of the esophagus and stomach. Semin Nucl Med. 2004; 34 198-208
- 3 Czernin J, Phelps M E. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53 89-112
- 4 Sciuk J, Hermann S, Franzius C. [Valence of F-18-FDG-PET in the diagnosis of malignant lymphoma]. Radiologe. 2002; 42 1000-1008
- 5 Schmidt M, Schmalenbach M, Jungehulsing M, Theissen P. et al . 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis. Nuklearmedizin. 2004; 43 91-101
- 6 Rosa F, Meimarakis G, Stahl A, Bumm R. et al . Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease. Nuklearmedizin. 2004; 43 135-140
- 7 Keppler J S. Federal regulations and reimbursement for PET. J Nucl Med Technol. 2001; 29 173-179
- 8 Reske S N, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, „Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med. 2001; 28 1707-1723
- 9 Dietlein M, Schicha H. [Reimbursement of the PET in oncology in Europe: a questionnaire based survey]. Nuklearmedizin. 2003; 42 80-85
- 10 Weber W A, Dietlein M, Hellwig D, Kirsch C M, Schicha H, Schwaiger M. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer]. Nuklearmedizin. 2003; 42 135-144
- 11 Block M I, Patterson G A, Sundaresan R S, Bailey M S. et al . Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997; 64 770-776
- 12 Choi J Y, Jang H J, Shim Y M, Kim K. et al . 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: Prognostic implications. J Nucl Med. 2004; 45 1843-1850
- 13 Choi J Y, Lee K H, Shim Y M, Lee K S. et al . Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med. 2000; 41 808-815
- 14 Flamen P, Lerut A, Cutsem E Van, De Wever W. et al . Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000; 18 3202-3210
- 15 Flanagan F L, Dehdashti F, Siegel B A, Trask D D. et al . Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997; 168 417-424
- 16 Kato H, Kuwano H, Nakajima M, Miyazaki T. et al . Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002; 94 921-928
- 17 Kim K, Park S J, Kim B T, Lee K S, Shim Y M. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001; 71 290-294
- 18 Westreenen H L van, Westerterp M, Bossuyt P M, Pruim J. et al . Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004; 22 3805-3812
- 19 Westreenen H L van, Heeren P A, Dullemen H M van, der Jagt E J van. et al . Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005; 9 54-61
- 20 Brucher B L, Weber W, Bauer M, Fink U. et al . Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001; 233 300-309
- 21 Downey R J, Akhurst T, Ilson D, Ginsberg R. et al . Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003; 21 428-432
- 22 Weber W A, Ott K, Becker K, Dittler H J. et al . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19 3058-3065
- 23 Weber W A, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol. 2004; 31 530-541
- 24 Theissen P, Schneider P M, Baldus S E, Jost A. et al . Monitoring of tumor response to neoadjuvant radio-chemotherapy of esophageal carcinoma by F-18-FDG-PET. Chinese German J Clin Oncol. 2004; 3 257-262
- 25 Fleming I D, Phillips J L, Menck H R, Murphy G P, Winchester D P. The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging. Cancer. 1997; 80 2305-2310
- 26 Lerut T, Flamen P, Ectors N, Cutsem E Van. et al . Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg. 2000; 232 743-752
- 27 Kato H, Miyazaki T, Nakajima M, Takita J. et al . The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005; 103 148-156
- 28 Flamen P, Lerut A, Cutsem E, Cambier J P. et al . The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000; 120 1085-1092
- 29 Kole A C, Plukker J T, Nieweg O E, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998; 78 521-527
- 30 Meltzer C C, Luketich J D, Friedman D, Charron M. et al . Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000; 25 882-887
- 31 Rankin S C, Taylor H, Cook G J, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol. 1998; 53 659-665
- 32 Jager P L, Que T H, Vaalburg W, Pruim J, Elsinga P, Plukker J T. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. Eur J Nucl Med. 2001; 28 1845-1849
- 33 Junginger T, Kneist W, Schreckenberger M, Menzel C, Oberholzer K, Bartenstein P. [Positron emission tomography for the preoperative staging of esophageal carcinoma]. Dtsch Med Wochenschr. 2002; 127 1935-1941
- 34 Wren S M, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg. 2002; 137 1001-1006
- 35 Yoon Y C, Lee K S, Shim Y M, Kim B T, Kim K, Kim T S. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology. 2003; 227 764-770
- 36 Westreenen H L van, Heeren P A, Jager P L, Dullemen H M van, Groen H, Plukker J T. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003; 10 1100-1105
- 37 Eloubeidi M A, Wallace M B, Hoffman B J, Leveen M B. et al . Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg. 2001; 72 212-219
- 38 Hulscher J B, Buskens C J, Bergman J J, Fockens P, Lanschot J J V, Obertop H. Positive peritruncal nodes for esophageal carcinoma. not always a dismal prognosis. Dig Surg. 2001; 18 98-101
- 39 Minn H, Leskinen-Kallio S, Lindholm P, Bergman J. et al . [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr. 1993; 17 115-123
- 40 Hölscher A H, Metzger R, Schneider P M. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?]. Zentralbl Chir. 2000; 125 319-325
- 41 Kies M S, Rosen S T, Tsang T K, Shetty R. et al . Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer. 1987; 60 2156-2160
- 42 Law S, Fok M, Chow S, Chu K M, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997; 114 210-217
- 43 Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Raemdonck D Van. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol. 2001; 10 113-122
- 44 Luketich J D, Schauer P, Urso K, Kassis E. et al . Future directions in esophageal cancer. Chest. 1998; 113 (Suppl 1) 120S-122S
- 45 Urba S G, Orringer M B, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19 305-313
- 46 Flamen P, Cutsem E, Lerut A, Cambier J P. et al . Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002; 13 361-368
- 47 Couper G W, Park K G. Detection of response to neoadjuvant therapy of esophageal squamous cell carcinoma by positron emission tomography (PET). Ann Surg. 2003; 237 289-290
- 48 Wieder H A, Brucher B L, Zimmermann F, Becker K. et al . Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004; 22 900-908
- 49 Swisher S G, Erasmus J, Maish M, Correa A M. et al . 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004; 101 1776-1785
- 50 Luketich J D, Friedman D M, Weigel T L, Meehan M A. et al . Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999; 68 1133-1136
Dr. Peter Theissen
Klinik und Poliklinik für Nuklearmedizin · Klinikum der Universität zu Köln
Kerpener Str. 62
50924 Köln
Germany
Phone: 02 21/4 78 58 56
Fax: 02 21/4 78 67 77
Email: peter.theissen@uni-koeln.de